At a glance
- Originator Merck Frosst
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics
- Mechanism of Action 5-lipoxygenase activating protein inhibitors; 5-lipoxygenase inhibitors; Leukotriene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 31 Aug 1998 No-Development-Reported for Asthma in USA (Unknown route)
- 31 Aug 1998 No-Development-Reported for Inflammatory bowel disease in USA (Unknown route)
- 31 Aug 1998 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)